X2ea5b654.8b53.4e39.8f1a.129a46474ae2
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.260
- PEROXISOME+0.240
- WNT_BETA_CATENIN_SIGNALING+0.240
- FATTY_ACID_METABOLISM+0.230
- TGF_BETA_SIGNALING+0.150
- BILE_ACID_METABOLISM+0.140
- HEME_METABOLISM+0.140
- HEDGEHOG_SIGNALING+0.130
- GLYCOLYSIS+0.120
- ADIPOGENESIS+0.090
Top 10 suppressed
- E2F_TARGETS-0.420
- G2M_CHECKPOINT-0.380
- ALLOGRAFT_REJECTION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- INFLAMMATORY_RESPONSE-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.280
- ANGIOGENESIS-0.270
- MTORC1_SIGNALING-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- IL6_JAK_STAT3_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.836 |
| 2 | SRR6013557 | — | cohortA1 | 0.827 |
| 3 | TCGA-NJ-A7XG-01A-12R-A39D-07 | — | cohortA1 | 0.826 |
| 4 | SRR12202454 | — | — | 0.825 |
| 5 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.825 |
| 6 | TCGA-55-8087-01A-11R-2241-07 | — | cohortA1 | 0.823 |
| 7 | C3N-02973 | — | cohortA1 | 0.813 |
| 8 | TCGA-73-7498-01A-12R-2187-07 | — | cohortA2 | 0.803 |
| 9 | C3L-00893 | — | cohortA1 | 0.800 |
| 10 | SRR6013579 | — | cohortA1 | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |